EXCLUSIVE: Ocean Biomedical Highlights New Results From Anti-Cancer Antibody Validating Tumor Suppression In Animal Models With Brain Tumor

Ocean Biomedical Inc's OCEA co-founder, Jack Elias, published new findings in the peer-reviewed journal Cancer Research detailing the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors.

What Happened: Results of the research uncovered new data on the efficacy of Ocean Biomedical's anti-Chi3L1 antibody in human glioblastoma implanted mouse models, resulting in a clear reduction in glioblastoma tumor growth.

The paper also revealed insights into the mechanisms underlying stem cell differentiation in glioma stem cells and how Ocean Biomedical's cancer therapeutic candidate alters that differentiation process.

In two different study approaches, treatment with anti-Chi3L1 antibody in vivo resulted in over 60% reduction of human glioblastoma growth and significant survival benefit.

Also Read: EXCLUSIVE: Ocean Biomedical's Co-Founder Outlines Detailed Data From Malaria Vaccine At Conference.

Why It Matters: "This is a completely new way of thinking about how to treat this tumor. Glioblastoma is so challenging partly because the cells adapt to the environment constantly – but if you block Chi3L1, they can't seem to acquire the more aggressive mesenchymal phenotype. It gives us a clear path forward to being able to address glioblastoma with this novel approach," said Dr. Nikos Tapinos, Director of the Laboratory of Cancer Epigenetics and Plasticity and the last author on the paper.

Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically.

Price Action: OCEA shares closed at $6.47 on Wednesday.